AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco
AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.
GSK secures China NMPA approval for Nucala in eosinophilic COPD, targeting hospitalisation risk
GSK PLC (LSE/NYSE: GSK) has received regulatory approval from the National Medical Products Administration of China for Nucala (mepolizumab) as an add-on maintenance therapy for adults with eosinophilic chronic obstructive pulmonary disease (COPD) inadequately controlled on inhaled triple therapy. The greenlight marks a strategic respiratory expansion for GSK in the world’s largest COPD market and […]